Health-tech companies have begun treating blood as the next data source to integrate into consumer platforms. The Verge's Victoria Song describes giving 24 vials this year—eight for an experimental "digital twin" and four for Death Clock, an app that estimates mortality from health data. Oura, Whoop, and Apple have partnered with Quest Diagnostics; Google has announced an integration with Function Health—so users can feed blood results into wellness products.
Death Clock's model illustrates the business logic. The app charges $69 a year and offers a "free" blood panel, then suggests optional tests for thyroid, heart, artery, and liver function, plus extra devices and screenings. The implied reward is longevity: Song's results projected she could gain 17 years by following the recommendations. Founder Brent Franson says people need to know what is happening in their bodies to take health seriously. He also concedes that the greatest predictor of longevity is socioeconomic status, not blood.
Blood is valuable to these companies because it is deeply personal data, but the user receives a vague promise rather than a guarantee. The column is a single first-person account, so there is no independent source to compare; its warning is that consumers may be trading a highly private biological stream for an estimate that even the seller admits has limits.